A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics

Journal of Infectious Diseases

Volumn 199, Issue 3, 2009, Pages 336-341

  Vietri, Nicholas J ^a   Purcell, Bret K ^a   Tobery, Steven A ^a   Rasmussen, Suzanne L ^a   Leffel, Elizabeth K ^a,c   Twenhafel, Nancy A ^a   Ivins, Bruce E ^a   Kellogg, Mark D ^a,d   Webster, Wendy M ^a   Wright, Mary E ^b   Friedlander, Arthur M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c National Biodefense Analysis and Countermeasures Center   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; BACTERIAL SPORE; DEATH; FEMALE; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; SPORE GERMINATION; SURVIVAL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; BIOTERRORISM; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; FEMALE; MACACA MULATTA; MALE; RANDOM ALLOCATION;

EID: 58849106368     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596063     Document Type: Article

References (30)

1. Brachman PS. Inhalation anthrax. Ann NY Acad Sci 1980; 353:83-93.
2. Holty JC, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-80.
3. Fritz DL, Jaax NK, Lawrence WB, et al. Pathology of experimental inhalational anthrax in the rhesus monkey. Lab Invest 1995; 73:691-702.
4. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 1957; 73:485-94.
5. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956; 54:28-36.
6. Barnes JM. Penicillin and B. anthracis. J Pathol Bacteriol 1947; 59:113-25.
7. Friedlander AM, Welkos SL, Pitt ML, et al. Post exposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239-43.
8. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci USA 2003; 100:10129-32.
9. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909-19.
10. Bossi P, Tengell A, Baka A, et al. BICHAT guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Task Force on Biological and Chemical Agent Threats, Public Health Directorate, European Commission, Luxembourg. Euro Surveill 2004; 9:E3-4.
11. Sirisanthana T, Nelson KE, Ezzell JW, Abshire TG. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg 1988; 39:575-81.
12. Buchanan TM, Feeley JC, Hayes PS, Brachman PS. Anthrax indirect microhemagglutination test. J Immunol 1971; 107:1631-6.
13. Quinn CP, Dull PM, Semenova V, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalational anthrax. J Infect Dis 2004; 190:1228-36.
14. Hodgson AE. Cutaneous anthrax. Lancet 1941; 1:811-3.
15. Vietri NJ, Purcell BK, Lawler JV, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 2006; 103:7813-6.
16. Lincoln RE, Klein F, Walker JS, et al. Successful treatment of rhesus monkeys for septicemic anthrax. Antimicrob Agents Chemother 1964; 10:759-63.
17. Ivins BE, Pitt, ML, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16:1141-8.
18. Tatti KM, Greer P, White E, et al. Morphologic, immunologic and molecular methods to detect Bacillus anthracis in formalin-fixed tissues. Appl Immunohistochem Mol Morphol 2006; 14:234-43.
19. Quinn CP, Semenova VA, Elie CM, et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002; 8:1103-10.
20. Cote CK, Rossi CA, Kang AS, Morrow PR, Lee JS, Welkos SL. The detection of protective antigen (PA) associated with the spores of B. anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 2005; 38:209-25.
21. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
22. Centers for Disease Control and Prevention. Notice to readers: additional options for preventive treatment for persons exposed to inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1142-3.
23. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993; 90:2291-4.
24. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019-28.
25. Marcus H, Danieli R, Epstein E, Velan B, Shafferman A, Reuveny S. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun 2004; 72:3471-7.
26. Jernigan, JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-44.
27. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related inhalational anthrax - Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1049-51.
28. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalational anthrax: clinical care and analysis of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968-71.
29. Friedlander AM. Anthrax - clinical features, pathogenesis, and potential biological warfare threat. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Vol 20. Oxford: Blackwell Science, 2000:335-49.
30. Tigertt WD, Benenson AS. Studies of Q fever in man. Trans Assoc Am Phys 1956; 69:98-104.